| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥1.8B | ¥2.0B | -11.4% |
| Operating Income | ¥-3.7B | ¥-3.8B | +2.9% |
| Ordinary Income | ¥-3.4B | ¥-3.5B | +3.7% |
| Net Income | ¥-3.4B | ¥-3.5B | +1.7% |
| ROE | -9.9% | -9.1% | - |
FY2026 Q1 results showed revenue of 1.8B yen (YoY -11.4%), operating loss of 3.7B yen (loss narrowed YoY +2.9%), ordinary loss of 3.4B yen (loss narrowed YoY +3.7%), and net loss of 3.4B yen (loss narrowed YoY +1.7%). Despite revenue contraction, losses improved slightly compared to the prior year period. The company maintains substantial cash reserves of 18.5B yen against current liabilities of only 2.9B yen, providing significant short-term liquidity cushion. However, structural profitability challenges persist with gross margin of 12.6% unable to absorb SG&A expenses of 3.9B yen, which represents 217.7% of revenue. Loss per share was 1.28 yen, marginally improved from 1.31 yen in the prior year. Full-year guidance projects continued losses with net loss of 14.5B yen anticipated, suggesting Q1 performance aligns with company expectations for ongoing restructuring phase.
Revenue declined 11.4% YoY to 1.8B yen, driven primarily by the Contract Cell Manufacturing segment which generated 1.8B yen with an operating loss of 1.3B yen and negative margin of 69.9%. The Cellular and Tissue Based Product segment contributed minimal revenue of 0.0B yen with an operating loss of 0.9B yen. Cost of sales was 1.6B yen, yielding gross profit of 0.2B yen at a gross margin of 12.6%, indicating limited pricing power or high production costs relative to sales. The primary profitability challenge stems from SG&A expenses of 3.9B yen, representing over twice the total revenue base. This structural cost burden drives the operating loss of 3.7B yen, equivalent to a negative operating margin of 205.0%.
Non-operating income of 0.4B yen partially offset operating losses, primarily comprising partnership gains of 0.3B yen. Extraordinary income of 0.1B yen from securities sales provided additional support. The gap between operating income of negative 3.7B yen and ordinary income of negative 3.4B yen reflects approximately 0.3B yen in net non-operating contributions. Tax expense was minimal at 0.0B yen given the loss position. Corporate expenses not allocated to segments totaled 0.2B yen. This represents a revenue down, loss marginally improved pattern, where top-line contraction is partially offset by modest expense management gains, though fundamental profitability remains significantly challenged by the fixed cost structure relative to the current revenue scale.
The Contract Cell Manufacturing segment serves as the core business, generating 1.8B yen in revenue with an operating loss of 1.3B yen and negative operating margin of 69.9%. This segment accounts for virtually all company revenue but remains deeply unprofitable as revenue cannot cover direct costs and allocated expenses. The Cellular and Tissue Based Product segment reported negligible revenue of 0.0B yen with operating loss of 0.9B yen and negative margin of 225,016.7%, indicating this remains in early development or commercialization stage with minimal market traction. Both segments show negative margins, with the Cellular and Tissue Based Product segment's extreme negative margin reflecting substantial ongoing investment without corresponding revenue generation. The core Contract Cell Manufacturing business requires significant revenue expansion or margin improvement to approach breakeven, while the nascent product segment represents longer-term optionality pending successful commercialization.
[Profitability] ROE of negative 9.9% reflects ongoing losses eroding equity base. Operating margin of negative 205.0% and net profit margin of negative 187.3% indicate severe structural profitability challenges where SG&A expenses substantially exceed gross profit generation. Gross margin of 12.6% provides limited contribution to cover fixed costs. [Cash Quality] Cash and deposits of 18.5B yen plus short-term investment securities of 10.0B yen total 28.5B yen in liquid assets, providing short-term debt coverage of 9.9 times against current liabilities of 2.9B yen. [Investment Efficiency] Asset turnover of 0.046 times reflects minimal revenue generation relative to total assets of 39.5B yen, indicating low capital productivity. [Financial Health] Equity ratio of 86.7% demonstrates strong capital foundation with total equity of 34.3B yen against total assets of 39.5B yen. Current ratio of 1,159.0% indicates substantial liquidity buffer. Debt-to-equity ratio of 0.15 shows minimal leverage with total liabilities of only 5.3B yen. Retained earnings of negative 17.0B yen reflect accumulated losses, though strong capital base provides runway for operations.
Cash and deposits decreased from prior year levels but remain substantial at 18.5B yen, while total liquid assets including short-term investment securities stand at 28.5B yen. The company maintains strong liquidity coverage with cash representing 6.4 times current liabilities of 2.9B yen. Working capital of 30.4B yen provides significant operational buffer. Trade receivables of 2.6B yen represent approximately 1.4 times quarterly revenue, suggesting extended collection cycles relative to the revenue run rate. Inventories remain minimal at 0.1B yen, appropriate for a service-oriented manufacturing model. Property, plant and equipment of 3.5B yen indicates moderate fixed asset investment. The balance sheet reflects continued operational cash consumption given ongoing losses, though the substantial liquid asset base provides multi-year runway at current loss rates. Total assets declined 7.1% from 42.5B yen to 39.5B yen, primarily driven by cash utilization to fund operations.
Ordinary income of negative 3.4B yen versus operating income of negative 3.7B yen shows net non-operating contribution of approximately 0.3B yen, equivalent to 16.6% of revenue. This comprises primarily partnership gains of 0.3B yen recognized in non-operating income. Extraordinary income of 0.1B yen from securities sales represents a one-time gain equivalent to 5.6% of revenue, categorized as non-recurring. Core operating losses of 3.7B yen represent the fundamental earnings power before financial adjustments. With operating margin deeply negative at 205.0%, underlying business operations consume approximately twice the revenue generated through fixed cost structures. The dependency on non-operating and extraordinary items to partially offset operating losses indicates earnings quality concerns, as sustainable profitability requires operating income improvement rather than reliance on external partnerships or asset sales.
Full-year guidance projects revenue of 9.4B yen, operating loss of 14.5B yen, ordinary loss of 14.5B yen, and net loss of 14.5B yen. Q1 revenue of 1.8B yen represents 19.1% progress against full-year target, slightly below the standard 25% quarterly pace, suggesting slower initial momentum with anticipated acceleration in remaining quarters or conservative pacing. Q1 operating loss of 3.7B yen represents 25.5% of projected full-year loss, indicating proportional loss progression. The forecast assumes full-year revenue growth of 16.4% YoY despite Q1 contraction, suggesting management expects significant revenue recovery in subsequent quarters. Forecast notes acknowledge substantial uncertainties inherent in projections based on currently available information. The guidance implies anticipated improvement trajectory with revenue rebuilding, though continued substantial losses throughout the fiscal year reflect ongoing investment phase and structural cost base optimization requirements before reaching sustainable profitability.
Annual dividend of 0.00 yen represents continuation of no dividend policy, unchanged YoY. Payout ratio is not applicable given the loss position. No share buyback activity was disclosed. Total return ratio stands at zero given absence of both dividends and buybacks. The no-dividend policy aligns appropriately with the company's current loss-making status and need to preserve capital for business development and operations. With net loss of 3.4B yen in Q1 and projected full-year loss of 14.5B yen, shareholder returns through capital distribution remain appropriately suspended. Cash preservation takes priority over distributions given the ongoing investment requirements and negative profitability. Return of capital to shareholders would require achievement of sustained profitability and positive cash generation from operations.
Revenue scale risk: Q1 revenue of 1.8B yen declined 11.4% YoY, and gross margin of only 12.6% provides minimal contribution to absorb fixed costs. Continued revenue shortfalls or pricing pressure would further extend the path to profitability. SG&A expenses of 3.9B yen represent 217.7% of revenue, creating substantial operating leverage risk.
Fixed cost structure risk: Operating losses of 3.7B yen and negative operating margin of 205.0% reflect structural mismatch between cost base and current revenue scale. Without significant revenue expansion or material cost restructuring, losses will continue depleting capital reserves. The company consumed approximately 3.4B yen of equity in Q1 alone, with accumulated deficit expanding to 17.0B yen.
Capital adequacy risk: While current liquid assets of 28.5B yen provide near-term runway, projected full-year net loss of 14.5B yen suggests approximately 2 years of operational runway at current loss rates before capital constraints emerge. Failure to achieve forecasted revenue growth of 16.4% or reduce loss rates could necessitate capital raising, potentially diluting existing shareholders.
[Industry Position] (Reference - Proprietary Analysis) Profitability: ROE negative 9.9% substantially underperforms industry median of 0.2% in IT and Telecom sector. Operating margin of negative 205.0% compares unfavorably to industry median of 5.3%, reflecting structural profitability challenges. Net profit margin of negative 187.3% versus industry median of 0.6% indicates severe earnings quality disadvantage. Financial Health: Equity ratio of 86.7% exceeds industry median of 68.9%, demonstrating superior capital strength and lower leverage relative to peers. This strong balance sheet provides financial flexibility unavailable to more leveraged competitors. Efficiency: Asset turnover of 0.046 times significantly trails industry median of 0.18 times, indicating inefficient asset utilization and revenue generation relative to capital deployed. Revenue growth of negative 11.4% underperforms industry median growth of 25.5%, suggesting market share loss or demand challenges. The company ranks at the bottom quartile for profitability and efficiency metrics while maintaining top quartile financial health through conservative capital structure. This positioning reflects a business in investment or restructuring phase with strong balance sheet supporting operations through negative cash flow period. (Industry: IT and Telecom sector, Comparison: 2025 Q1, n=3 companies, Source: Proprietary analysis)
Financial fortress amid operational challenges: The company maintains exceptional liquidity with 28.5B yen in cash and short-term securities against only 2.9B yen in current liabilities, providing 9.9 times coverage and approximately 2 years of runway at projected full-year loss rates. Equity ratio of 86.7% ranks top quartile versus industry peers, offering substantial downside protection and strategic flexibility uncommon among loss-making enterprises.
Structural profitability gap requiring transformation: Operating margin of negative 205.0% with SG&A expenses representing 217.7% of revenue indicates fundamental business model misalignment between current revenue scale and fixed cost structure. The company's gross margin of 12.6% trails far behind the breakeven requirement, with both segments unprofitable. Management's full-year guidance projecting 16.4% revenue growth while Q1 contracted 11.4% suggests anticipated inflection, though execution risk remains elevated given the magnitude of required improvement to approach breakeven operations.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.